PMID- 9130648 OWN - NLM STAT- MEDLINE DCOM- 19970522 LR - 20151123 IS - 0014-2980 (Print) IS - 0014-2980 (Linking) VI - 27 IP - 4 DP - 1997 Apr TI - HLA-DR-restricted presentation of purified myelin basic protein is independent of intracellular processing. PG - 941-51 AB - Antigen presentation to CD4+ T cells involves intracellular antigen processing and loading of peptides onto newly synthesized major histocompatibility complex (MHC)-class II molecules. Some antigens, such as the lipid-bound, native form of myelin basic protein (LB-MBP) can also be presented by recycling of cell surface MHC class II molecules. The data reported here demonstrate that a preparation of highly purified, delipidated MBP (HP-MBP) follows yet another presentation pathway. Similar to LB-MBP, presentation of HP-MBP to HLA-DR1-restricted T cells was independent of HLA-DM, of newly synthesized proteins, and of invariant chain expression. However, in contrast to LB-MBP, presentation of HP-MBP was also independent of internalization of surface HLA-DR molecules. The different requirements for the presentation of the two molecular forms of MBP were further confirmed by use of the protease inhibitor E64: presentation of LB-MBP but not of HP-MBP was inhibited after treatment of target cells with E64. Furthermore, intact HP-MPB bound to isolated HLA-DR molecules in vitro with an association rate that was considerably faster than that of short peptides. These results show that presentation of HP-MBP is independent of intracellular processing and suggest that it may be presented to T cells by direct binding to surface HLA-DR molecules. FAU - Vergelli, M AU - Vergelli M AD - Neuroimmunology Branch, NINDS, NIH, Bethesda, MD 20892-1400, USA. FAU - Pinet, V AU - Pinet V FAU - Vogt, A B AU - Vogt AB FAU - Kalbus, M AU - Kalbus M FAU - Malnati, M AU - Malnati M FAU - Riccio, P AU - Riccio P FAU - Long, E O AU - Long EO FAU - Martin, R AU - Martin R LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Germany TA - Eur J Immunol JT - European journal of immunology JID - 1273201 RN - 0 (Antigens, Differentiation, B-Lymphocyte) RN - 0 (Cysteine Proteinase Inhibitors) RN - 0 (HLA-DR1 Antigen) RN - 0 (Histocompatibility Antigens Class II) RN - 0 (Myelin Basic Protein) RN - 0 (invariant chain) RN - GMW67QNF9C (Leucine) RN - R76F7856MV (E 64) SB - IM MH - *Antigen Presentation/drug effects MH - Antigens, Differentiation, B-Lymphocyte/immunology/metabolism MH - Chromatography, High Pressure Liquid MH - Clone Cells MH - Cysteine Proteinase Inhibitors/pharmacology MH - HLA-DR1 Antigen/*immunology/isolation & purification/*metabolism MH - Histocompatibility Antigens Class II/immunology/metabolism MH - Humans MH - Intracellular Fluid/immunology/*metabolism MH - Leucine/analogs & derivatives/pharmacology MH - Lipid Metabolism MH - Myelin Basic Protein/*immunology/*metabolism MH - Protein Binding/immunology MH - T-Lymphocytes/immunology/metabolism EDAT- 1997/04/01 00:00 MHDA- 1997/04/01 00:01 CRDT- 1997/04/01 00:00 PHST- 1997/04/01 00:00 [pubmed] PHST- 1997/04/01 00:01 [medline] PHST- 1997/04/01 00:00 [entrez] AID - 10.1002/eji.1830270421 [doi] PST - ppublish SO - Eur J Immunol. 1997 Apr;27(4):941-51. doi: 10.1002/eji.1830270421.